Macular degeneration
Drug Safety Update
January 2022: Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals
July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
April 2016: Aflibercept (Zaltrap▼): minimising the risk of osteonecrosis of the jaw
NICE Guidance (see also drug specific links below)
NG82: Age-related macular degeneration, January 2018.
Local guidelines for the treatment of wet AMD with anti-VEGF agents- see here
These drugs are for specialist use only and should be used in accordance with NICE guidance.
Aflibercept is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF-A, VEGF-B and the placental growth factor. It is an option for treating neovascular (wet) age-related macular degeneration, diabetic macular oedema and macular oedema secondary to central retinal vein occulsion.
Brolucizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby suppressing endothelial cell proliferation and inhibiting the growth of new vessels and decreasing vascular permeability. It is licensed for use in the treatment of neovascular (wet) age-related macular degeneration and diabetic macular oedema.
Faricimab is a bispecific immunoglobulin G1 antibody that inhibits angiopoietin-2 and vascular endothelial growth factor A, thereby inactivating angiogenesis, reducing vascular inflammation and restoring vascular stability. It is used for the treatment of Neovascular (wet) age-related macular degeneration and diabetic macular oedema.
Ranibizumab is a vascular endothelial growth factor A (VEGF-A) inhibitor used for the treatment of neovascular (wet) age-related macular degeneration, diabetic macular oedema and macular oedema due to retinal vein occlusion.
Verteporfin is licensed for use in the photodynamic treatment of wet age-related macular degeneration with a confirmed diagnosis of classic subfoveal choroidal neovascularisation.
One pre-filled syringe contains an extractable volume of at least 0.09 mL, equivalent to at least 3.6 mg aflibercept. This provides a usable amount to deliver a single dose of 0.05 mL containing 2 mg aflibercept to adult patients.
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | £816.00 |
One vial contains an extractable volume of at least 0.1 mL, equivalent to at least 4 mg aflibercept. This provides a usable amount to deliver a single dose of 0.05 mL containing 2 mg aflibercept.
| Pack | Price |
|---|---|
| 1 vial | £816.00 |
Each vial contains 30.1 mg aflibercept in 0.263 ml solution. This provides a usable amount to deliver a single dose of 0.07 ml containing 8 mg aflibercept.
| Pack | Price |
|---|---|
| 1 vial | £998.00 |
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | £816.00 |
| Pack | Price |
|---|---|
| 1 pre-filled disposable injection | £551.00 |
| Pack | Price |
|---|---|
| 1 vial | £551.00 |
| Pack | Price |
|---|---|
| 1 vial | £523.45 |